DiaMedica Therapeutics Inc. Operating Income
DiaMedica Therapeutics Inc. (DMAC) reported Operating Income of -$10.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- DiaMedica Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$10.50M.
- DiaMedica Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$10.48M.
- DiaMedica Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$9.21M.
- DiaMedica Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$9.03M.
- DiaMedica Therapeutics Inc. operating income (loss) for fiscal 2025 was -$34.40M.
- DiaMedica Therapeutics Inc. operating income (loss) for fiscal 2024 was -$26.68M.
- DiaMedica Therapeutics Inc. operating income (loss) for fiscal 2023 was -$21.27M.
- DiaMedica Therapeutics Inc. operating income (loss) for fiscal 2022 was -$14.00M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.50M 10-Q · filed 2026-08-10 | -$20.98M 10-Q · filed 2026-08-10 | -$30.19M derived: sum of 3 quarters · filed 2026-08-10 | -$39.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$10.48M 10-Q · filed 2026-05-06 | -$19.70M derived: sum of 2 quarters · filed 2026-05-06 | -$28.73M derived: sum of 3 quarters · filed 2026-05-06 | -$36.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$18.25M derived: sum of 2 quarters · filed 2026-03-30 | -$26.25M derived: sum of 3 quarters · filed 2026-08-10 | -$34.40M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$9.03M 10-Q · filed 2025-11-12 | -$17.04M derived: sum of 2 quarters · filed 2026-08-10 | -$25.18M 10-Q · filed 2025-11-12 | -$33.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$8.01M 10-Q · filed 2026-08-10 | -$16.15M 10-Q · filed 2026-08-10 | -$24.57M derived: sum of 3 quarters · filed 2026-08-10 | -$31.45M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$8.14M 10-Q · filed 2026-05-06 | -$16.56M derived: sum of 2 quarters · filed 2026-05-06 | -$23.45M derived: sum of 3 quarters · filed 2026-05-06 | -$29.08M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$8.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$15.30M derived: sum of 2 quarters · filed 2026-03-30 | -$20.94M derived: sum of 3 quarters · filed 2026-03-30 | -$26.68M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$6.88M 10-Q · filed 2025-11-12 | -$12.52M derived: sum of 2 quarters · filed 2025-11-12 | -$18.26M 10-Q · filed 2025-11-12 | -$24.11M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.64M 10-Q · filed 2025-08-12 | -$11.38M 10-Q · filed 2025-08-12 | -$17.23M derived: sum of 3 quarters · filed 2025-08-12 | -$22.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$5.74M 10-Q · filed 2025-05-13 | -$11.59M derived: sum of 2 quarters · filed 2025-05-13 | -$16.75M derived: sum of 3 quarters · filed 2025-05-13 | -$21.49M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$11.01M derived: sum of 2 quarters · filed 2025-03-17 | -$15.75M derived: sum of 3 quarters · filed 2025-03-17 | -$21.27M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$5.16M 10-Q · filed 2024-11-13 | -$9.90M derived: sum of 2 quarters · filed 2024-11-13 | -$15.42M 10-Q · filed 2024-11-13 | -$19.39M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$4.74M 10-Q · filed 2024-08-07 | -$10.26M 10-Q · filed 2024-08-07 | -$14.23M derived: sum of 3 quarters · filed 2024-08-07 | -$17.36M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$5.52M 10-Q · filed 2024-05-08 | -$9.49M derived: sum of 2 quarters · filed 2024-05-08 | -$12.62M derived: sum of 3 quarters · filed 2024-05-08 | -$15.99M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$7.10M derived: sum of 2 quarters · filed 2024-03-19 | -$10.46M derived: sum of 3 quarters · filed 2024-03-19 | -$14.00M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$3.13M 10-Q · filed 2023-11-13 | -$6.49M derived: sum of 2 quarters · filed 2023-11-13 | -$10.03M 10-Q · filed 2023-11-13 | -$13.27M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$3.36M 10-Q · filed 2023-08-14 | -$6.90M 10-Q · filed 2023-08-14 | -$10.15M derived: sum of 3 quarters · filed 2023-08-14 | -$13.56M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.54M 10-Q · filed 2023-05-15 | -$6.78M derived: sum of 2 quarters · filed 2023-05-15 | -$10.20M derived: sum of 3 quarters · filed 2023-05-15 | -$13.56M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$6.66M derived: sum of 2 quarters · filed 2023-03-28 | -$10.03M derived: sum of 3 quarters · filed 2023-03-28 | -$13.65M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$3.42M 10-Q · filed 2022-11-09 | -$6.78M derived: sum of 2 quarters · filed 2022-11-09 | -$10.40M 10-Q · filed 2022-11-09 | -$14.67M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$3.37M 10-Q · filed 2022-08-11 | -$6.98M 10-Q · filed 2022-08-11 | -$11.25M derived: sum of 3 quarters · filed 2022-08-11 | -$14.57M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$3.62M 10-Q · filed 2022-05-04 | -$7.89M derived: sum of 2 quarters · filed 2022-05-04 | -$11.21M derived: sum of 3 quarters · filed 2022-05-04 | -$13.91M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$7.59M derived: sum of 2 quarters · filed 2022-03-14 | -$10.29M derived: sum of 3 quarters · filed 2022-03-14 | -$12.70M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$3.32M 10-Q · filed 2021-11-10 | -$6.03M derived: sum of 2 quarters · filed 2021-11-10 | -$8.43M 10-Q · filed 2021-11-10 | -$11.20M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$2.71M 10-Q · filed 2021-08-11 | -$5.11M 10-Q · filed 2021-08-11 | -$7.88M derived: sum of 3 quarters · filed 2021-08-11 | -$10.54M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$2.40M 10-Q · filed 2021-05-05 | -$5.17M derived: sum of 2 quarters · filed 2021-05-05 | -$7.83M derived: sum of 3 quarters · filed 2021-05-05 | -$10.58M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | -$5.43M derived: sum of 2 quarters · filed 2021-03-10 | -$8.17M derived: sum of 3 quarters · filed 2021-03-10 | -$11.59M 10-K · filed 2021-03-10 |
| 2019-09-30 | -$2.66M 10-Q · filed 2020-11-04 | -$5.40M derived: sum of 2 quarters · filed 2020-11-04 | -$8.82M 10-Q · filed 2020-11-04 | -$10.94M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$2.74M 10-Q · filed 2020-08-11 | -$6.16M 10-Q · filed 2020-08-11 | -$8.28M derived: sum of 3 quarters · filed 2020-08-11 | -$9.77M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$3.42M 10-Q · filed 2020-05-13 | -$5.54M derived: sum of 2 quarters · filed 2020-05-13 | -$7.03M derived: sum of 3 quarters · filed 2020-05-13 | -$8.88M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | -$3.60M derived: sum of 2 quarters · filed 2020-03-23 | -$5.45M derived: sum of 3 quarters · filed 2020-03-23 | -$6.76M 10-K · filed 2020-03-23 |
| 2018-09-30 | -$1.49M 10-Q · filed 2019-11-13 | -$3.34M derived: sum of 2 quarters · filed 2019-11-13 | -$4.64M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$1.85M 10-Q · filed 2019-08-13 | -$3.16M 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$1.31M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | -$4.52M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |